Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios A Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michèle Cavo, Meral Beksaç, Wojciech Legieć, Anna Marina Liberati, Hartmut Goldschmidt, Andrew R. Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria Teresa Petrucci, Donna Reece, Darrell White, María‐Victoria Mateos, Ivan Špıčka, Mihaela Lazaroiu, Jesús G. Berdeja, Jonathan L. Kaufman, Ying‐Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Meletios A Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michèle Cavo, Meral Beksaç, Wojciech Legieć, Anna Marina Liberati, Hartmut Goldschmidt, Andrew R. Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria Teresa Petrucci, Donna Reece, Darrell White, María‐Victoria Mateos, Ivan Špıčka, Mihaela Lazaroiu, Jesús G. Berdeja, Jonathan L. Kaufman, Ying‐Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Irwindeep Sandhu, Monika Podhorecka, Antonio Palumbo, Adi Shacham‐Abulafia, Iuliana Vaxman, Ofer Shpilberg, Britta Besemer, Maurizio Martelli, Roberto Foà, Paolo de Fabritiis, Tommaso Caravita di Toritto, Emanuil Gheorghita, Albert Oriol, Philip Rowlings, Angelucci Emanuele, Angelo Michele Carella, Massimo Offidani, Joan Bladé, Luis Felipe Casado, Heather Oakervee, Victoria Panelli, Luís Meza, Thomas Kühr, Miguel Granell, Don Benson, Rajesh Nair, Viran Holden, J. N. Reeves, Richard Eek, Patricia Walker, John Catalano, András Rosta, Ewa Lech‐Marańda, Christy Samaras, Tony Reiman, Robert Weaver, Péter Ács, Andrew Grigg, Bernard De Prijck, Martha Louzada, Leonard Minuk, Michaël Sébag, Martine Klausmann, Manfred Welslau, Andrzej Hellmann, Catalin Danaı̈la, Pamela S. Becker, William Bensinger (2022). Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. , 9(6), DOI: https://doi.org/10.1016/s2352-3026(22)00103-x.